Top Analysts Pick 3 Stocks with 300% Upside Potential

Three stocks to buy now, according to top analysts, are Larimar Therapeutics (LRMR), Chipotle (CMG), and Spire Global (SPIR). All three stocks have received new Buy ratings and have significant upside potential. Larimar Therapeutics has a 304.93% upside, Chipotle has a 35.77% upside, and Spire Global has a 51.75% upside. TipRanks' Analyst Top Stocks tool can help investors find more stocks like these.

In the dynamic landscape of the stock market, analysts' ratings can serve as valuable indicators for investors. According to recent analyses, Larimar Therapeutics (LRMR), Chipotle (CMG), and Spire Global (SPIR) have received new Buy ratings, each with significant upside potential. Here's a breakdown of these stocks:

Larimar Therapeutics (LRMR)
Larimar Therapeutics has maintained a strong Buy rating with a price target of $26.00 from Guggenheim [1]. The stock is currently trading at $4.24, suggesting a potential 304.93% upside. Analysts have a strong consensus, with price targets ranging from $10 to $40. Larimar is expected to present initial open-label extension (OLE) data in September 2025, which could provide significant catalysts for the stock. The company has also extended its cash runway into the fourth quarter of 2026 following a recent capital raise.

Chipotle (CMG)
Chipotle has received a new Buy rating with a price target of $475.00 from TipRanks, suggesting a 35.77% upside. The stock is currently trading at $350.00. Chipotle's strong financial performance and growing market share have positioned it as a favorite among analysts.

Spire Global (SPIR)
Spire Global has been given a new Buy rating with a price target of $37.00 from TipRanks, indicating a 51.75% upside. The stock is currently trading at $24.00. Spire Global's focus on environmental, social, and governance (ESG) factors, along with its innovative technology, has attracted analyst interest.

These stocks offer compelling upside potential based on analyst ratings. Investors should consider these opportunities carefully, taking into account their own risk tolerance and investment goals. For more insights, consider using tools like TipRanks' Analyst Top Stocks tool.

References:
[1] https://za.investing.com/news/analyst-ratings/larimar-therapeutics-stock-maintains-buy-rating-at-guggenheim-ahead-of-key-data-93CH-3841174